Objective. Acute allergic reactions are important causes of Emergency Department (ED) admissions. Although the current recommendations for treatment of patients with anaphylaxis are focused on the central role of adrenaline, evidence in support of this therapy is still scarce. We planned a retrospective analysis of all allergic and anaphylactic reactions managed in the ED, to assess adherence to current guidelines and clinical outcomes.
Introduction
Acute allergic reactions are important causes of Emergency Department (ED) admissions, the frequency of which has exhibited an incremental trend in the past decades. (1,2) Alongside allergic rhinitis, which is an infrequent cause of ED visits, and asthma (i.e., a separate disease), the most frequent types of acute allergic reactions include acute urticaria, acute angioedema and anaphylaxis, as well as an overlap of these acute conditions. Although acute urticaria is considered a self-limiting disease in the vast majority of cases, it might occasionally be associated with angioedema, or else be an important symptom of anaphylactic episodes. exists about the precise definition, so that only 1% of ED admissions for acute systemic allergic reactions are correctly diagnosed as anaphylaxis, whereas most cases are classified as "acute allergic reactions" or "acute hypersensitivity reactions". (7, 8) From a clinical perspective, anaphylaxis should also be regarded as a continuous rather than a dichotomous state, and this probably entails different management strategies .
Although the current recommendations for treatment of patients with anaphylactic reactions are focused on the central role of adrenaline (also known as epinephrine), the evidence in support of this therapeutic approach is scarce due to the lack of well-designed controlled trials. 
Materials and methods
The study population consisted of all consecutive adult patients admitted 
Results
A total number of 3237 records were analyzed by two separate physicians after first extraction, in order to exclude erroneous or dubious entries.
Children aged 16 years or younger (n=273 cases) were not included since they are usually seen in the Pediatric Clinic of our hospital and not by Emergency Physicians (EPs). Cases of allergic rhinitis, asthma and chronic urticaria were also excluded (n=2376), so that the analysis was Network symposium, (5) and of the World Allergy Organization guidelines for the assessment and management of anaphylaxis. (12) Overall, the final study population consisted of 589 patients, i.e., 329 women and 260 men (55.9% vs. 44.1%, mean age 43±18 years, range 16-96 years), representing 0.65% of all ED admissions throughout the study period. All patients arrived to the ED prior to 12 hours from onset of symptoms and none of them were admitted more than once for acute allergic reactions during the study period. No patients had adrenaline administered) before ED arrival, i.e., self-administered or from prehospital providers. Fifty-six patients met the diagnostic criteria for anaphylaxis (9.5%), 75 for angioedema (12.7%), 363 for urticaria (61.7%), and 95 for urticaria-angioedema (16.1%). The suspected triggers of allergic reactions were drugs (n=129; 21.9%), food (n=88; 15.0%), hymenoptera stings (n=58; 9.9%) and chemicals (n=26; 4.4%), whereas a specific cause could not be recognized in nearly half of cases (n=288; 48.9%). In the subgroup of patients with anaphylaxis, the triggers were 
Discussion
The results of our study show that anaphylaxis is widely undertreated with adrenaline in our local ED compared to current guidelines and recommendations, and this is in agreement with previous reports. (11,14- 
17)
The significant diagnostic uncertainty is indeed one of the leading problems for diagnosing and treating anaphylaxis. An international and interdisciplinary group of experts attempted to establish clinical criteria for increasing the accuracy in diagnosing anaphylaxis during the US National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) and the Food Allergy and Anaphylaxis Network (Chantilly, VA, USA) convened symposia. (5) The adopted working definition was as follows: "Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death". The group also proposed that anaphylaxis is likely to be clinically present if any one of three major criteria is satisfied within minutes to hours: (i) acute onset of illness with involvement of skin, mucosal surface, or both, and at least one of the following: respiratory compromise, hypotension, or end-organ dysfunction; (ii) two or more of the following occur rapidly after exposure to a likely allergen: involvement of skin or mucosal surface, respiratory compromise, hypotension, or persistent gastrointestinal symptoms; and (iii) hypotension develops after exposure to a known allergen for that patient: age-specific low blood pressure or decline of systolic blood pressure of >30% compared to baseline. (5) The group concluded that these criteria "are likely to capture more than 95% of cases of anaphylaxis". However, the report also states that "There undoubtedly will be patients who present with symptoms not yet fulfilling the criteria of anaphylaxis yet in whom it would be appropriate to initiate therapy with epinephrine, such as a patient with a history of near-fatal anaphylaxis to peanut who ingested peanut and within minutes is experiencing urticaria and sting. (19) In our study, the percentage of unknown triggers for anaphylaxis was 19.6%, which is in agreement with that reported in the recent literature A recent Cochrane review on adrenaline as a treatment of anaphylaxis failed to report any evidence from prospective, randomized or quasirandomized trials on the effectiveness of this drug for emergency management of anaphylaxis. (27) This lack of evidence was mainly attributed to the relative infrequency of severe anaphylactic reactions, the rapid onset, the often unexpected occurrence, as well as by the widely accepted role of adrenaline in various clinical settings. (13, 27) In conclusion, the results of our study suggest that anaphylaxis seems to SIGNA VITAE 2016; 11(1): be widely undertreated with adrenaline in our local ED compared to exiting guidelines and recommendations, and this is in agreement with previous reports. (11, (14) (15) (16) (17) Nevertheless, a favorable outcome was recorded for all patients included in this study, even when managed with second-and third-line treatments. In fact, no death was observed at 1 month and the number of hospitalizations was very limited (3/589; 0.5%), mainly due to comorbidities rather than to treatment failure. We hence assume that these findings should be addressed as food for thought for reconsidering the validity of recommendations contained in current guidelines. 
